Diagnostic value of gamma-glutamyltransferase/aspartate aminotransferase ratio, protein induced by vitamin K absence or antagonist II, and alpha-fetoprotein in hepatitis B virus-related hepatocellular carcinoma

Table 2 Performance of protein induced by vitamin K absence or antagonist II, alpha-fetoprotein, and the ratio of gamma-glutamyltransferase to aspartate aminotransferase in early-stage hepatocellular carcinoma and hepatocellular carcinoma

	Early-stage HCC					HCC
	Cut-off	SEN (%)	SPE (%)	PPV (%)	NPV (%)	Cut-off	SEN (%)	SPE (%)	PPV (%)	NPV (%)
PIVKA-II (mAu/mL)	84.44	68.90	89.70	57.96	93.33	162.22	81.30	93.60	86.16	91.08
AFP (ng/mL)	145.65	47.30	77.20	29.95	87.66	145.65	64.80	77.20	58.22	81.73
γ-GT/AST	0.845	78.40	64.90	31.53	93.58	0.845	81.80	64.90	53.33	87.91
PIVKA-II + AFP	NA	60.80	90.80	57.67	91.83	NA	73.30	93.90	85.49	87.77
PIVKA-II + γ-GT/AST	NA	74.30	86.60	53.34	94.24	NA	86.90	83.80	72.45	92.88
AFP + γ-GT/AST	NA	56.80	81.90	39.28	90.19	NA	76.10	76.30	61.15	86.69
PIVKA-II + AFP + γ-GT/AST	NA	73.00	82.50	46.23	93.68	NA	78.40	91.10	81.20	89.59

HCC: Hepatocellular carcinoma; SEN: Sensitivity; SPE: Specificity; PPV: Positive predictive value; NPV: Negative predictive value; PIVKA-II: Protein induced by vitamin K absence or antagonist II; AFP: Alpha-fetoprotein; γ-GT/AST: The ratio of gamma-glutamyltransferase to aspartate aminotransferase; NA: Not applicable.